Preoperative chemotherapy for women with operable breast cancer
about
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerAACR Cancer Progress Report 2014Optimal management of breast cancer in the elderly patient: current perspectivesOncoplastic breast surgery: current strategiesEfficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trialsPathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapyMeta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyCirculating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer.Impact of neoadjuvant chemotherapy on immediate breast reconstruction: a meta-analysis.Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancerMagnetic resonance imaging shrinkage patterns following neoadjuvant chemotherapy for breast carcinomas with an emphasis on the radiopathological correlationsTherapeutic options for HER-2 positive breast cancer: Perspectives and future directionsTopo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy.Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast CancerNeoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction.Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?Review of breast conservation therapy: then and nowSafety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.Texture analysis on MR images helps predicting non-response to NAC in breast cancerHigher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapyPlatelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast CancerClinical implications of molecular heterogeneity in triple negative breast cancer.Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer.Population and target considerations for triple-negative breast cancer clinical trials.Targets for Neoadjuvant Therapy - The Preferences of Patients with Early Breast Cancer.A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO).Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women with Chemotherapy-Induced Cognitive Impairment.Association of PTP1B with Outcomes of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy.Treatment response assessment of breast masses on dynamic contrast-enhanced magnetic resonance scans using fuzzy c-means clustering and level set segmentationThe Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast CancerNeoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.Neoadjuvant chemotherapy in breast cancers.Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging
P2860
Q26785612-CA1EF8C6-49B6-4B04-93A5-CC49A3E94790Q27346723-A71F2BA0-D631-49BE-9397-EDD2D14A45C4Q27690879-F7D60867-BF5E-414A-943A-5A5DC34E0B1AQ28082147-38312D39-DED9-441F-85F5-E42B96935F03Q33438050-81BA1A1F-8935-417A-83A4-F70FE9B7DE0CQ33566963-FA476F9F-7DBA-4D25-8D69-9D0872BCD54AQ33573055-2E5205B6-C033-4D90-AABB-01BC6783C4B6Q33668173-5F7BF110-84CB-4707-9940-01173161F496Q33690155-E1E89E69-6553-4EFC-918F-179CA8B58F7BQ33730822-BCBE544D-4808-46BA-8DED-EA784C60CAAEQ33933029-954D7FB6-64A9-4CC0-8253-8B22E5CFD514Q34023704-CBB2090F-B106-468A-9042-9A58FEDDDFD3Q34433737-9FA6A4CE-5D1B-4CDD-8F20-C3C80525EF4AQ34457064-56143C71-A335-447C-8CDC-1F130BC41404Q34984314-F4F6C0F3-1E2C-4FAF-88E8-936D212017F0Q35149726-4AF33D0E-B701-4C08-8B23-4C04C31AE1E0Q35155591-F023BB30-AAAB-46D8-B966-C9EB213118F8Q35160045-DD05226C-4FC7-4826-8DFD-17C78F6478EAQ35433289-B5EE2962-7581-4F59-89E7-A0028822C6C8Q35530220-01D23B4A-D8CB-431F-984F-FE1B72312387Q35599471-E06B22C6-4B68-43A0-A974-37A789E7B9B6Q35737991-D2DC811D-28A7-479C-9F34-E8914684DA55Q35901372-867C7E94-F403-4750-ABCB-DCD9F839DAF2Q36089813-8833F907-97AE-4657-8A1B-20B2EB480DFAQ36271396-778870DA-4EFC-4071-99A7-9D8B58E7A9BDQ36473017-7146C21A-F065-4AFD-B3B5-3F0DEEABC58EQ36637292-37EABE6E-4C66-4107-92A5-B830AC217DBBQ36649503-DEA88F14-35F5-405E-949D-5B2931AA539FQ36914142-1DF9DE31-664A-49AB-AD80-3211D256925FQ36914317-0F6D3F10-C35D-44D8-BF3B-08457BA1FBD9Q36917634-AC196920-22E8-4B85-8C6B-C48ECD3386CAQ36968921-71CA7083-0529-47E8-B68D-DF518DCB374DQ37145188-231DAE40-67DF-4E20-AF06-9220EBD9015DQ37242525-A606E47A-DAF8-42C8-A875-703F7167FAB1Q37397626-AA083ECE-CA6B-4B35-92A6-FC227479180BQ37412241-117FD97E-1B73-4C3E-86C7-4AE779231728Q37720246-34EA3140-6F0E-4EA9-ACEA-DE37CD279F47Q38970049-D41B9ECF-0C0B-4AB5-8CE8-3F7E1514370DQ39019234-5FF4E7B1-9B9B-4C26-83AB-56D28C167294Q41276299-D210A19D-F288-4C1C-B91F-B1570FEF7498
P2860
Preoperative chemotherapy for women with operable breast cancer
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Preoperative chemotherapy for women with operable breast cancer
@ast
Preoperative chemotherapy for women with operable breast cancer
@en
Preoperative chemotherapy for women with operable breast cancer
@en-gb
Preoperative chemotherapy for women with operable breast cancer
@nl
type
label
Preoperative chemotherapy for women with operable breast cancer
@ast
Preoperative chemotherapy for women with operable breast cancer
@en
Preoperative chemotherapy for women with operable breast cancer
@en-gb
Preoperative chemotherapy for women with operable breast cancer
@nl
prefLabel
Preoperative chemotherapy for women with operable breast cancer
@ast
Preoperative chemotherapy for women with operable breast cancer
@en
Preoperative chemotherapy for women with operable breast cancer
@en-gb
Preoperative chemotherapy for women with operable breast cancer
@nl
P2093
P2860
P3181
P1476
Preoperative chemotherapy for women with operable breast cancer
@en
P2093
Cornelis CJH van de Velde
Jos H van der Hage
Sven JSD Mieog
P2860
P3181
P356
10.1002/14651858.CD005002.PUB2
P577
2007-04-18T00:00:00Z